There are now two drugmakers seeking emergency use authorization for their coronavirus vaccines.
Moderna is joining Pfizer in filing for the special status. It says its vaccine is 94 percent effective in trials, on par with the 95 percent announced by Pfizer when it made its request about a week ago.
Like Pfizer’s version, Moderna’s vaccine would be delivered in two settings. Moderna expects to make 20 million doses by the end of December, or enough for 10 million patients. It’s also seeking emergency authorization globally with the potential of making upwards of a billion doses next year.
Pfizer has an FDA hearing Dec. 10. It’s projecting 50 million doses created by the end of the year and over 1 billion doses next year.
A date for the Moderna hearing will be announced later.
